SecSonar.com

Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Contineum Therapeutics, Inc. Class A Common Stock at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Biotechnology company based in US with a market capitalization of $499.1M. Free cash flow was negative at -$55.5M. This page tracks CTNM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 41 employees · IPO Apr 5, 2024

Valuation

Valuation & price

$13.72 · as of May 17, 2026 · -14.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.91

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$16.00$9.88$3.77Jul 25Dec 25Jun 26Jul 7, 25$3.81Jul 9, 25$4.01Jul 11, 25$3.92Jul 15, 25$3.77Jul 17, 25$3.84Jul 21, 25$5.65Jul 23, 25$5.50Jul 25, 25$5.77Jul 29, 25$5.20Jul 31, 25$5.90Aug 4, 25$5.80Aug 6, 25$6.33Aug 8, 25$6.47Aug 12, 25$6.75Aug 14, 25$7.26Aug 19, 25$9.30Aug 21, 25$10.04Aug 25, 25$10.39Aug 27, 25$10.01Aug 29, 25$10.45Sep 3, 25$10.58Sep 5, 25$11.50Sep 9, 25$12.52Sep 11, 25$11.81Sep 15, 25$12.39Sep 17, 25$12.39Sep 19, 25$12.50Sep 23, 25$11.06Sep 25, 25$10.86Sep 29, 25$11.82Oct 2, 25$10.75Oct 6, 25$11.08Oct 8, 25$12.16Oct 10, 25$11.88Oct 14, 25$11.67Oct 16, 25$12.46Oct 20, 25$11.09Oct 22, 25$11.03Oct 24, 25$11.05Oct 28, 25$11.03Oct 30, 25$10.54Nov 3, 25$10.65Nov 5, 25$10.44Nov 7, 25$10.93Nov 11, 25$10.96Nov 14, 25$10.66Nov 18, 25$11.51Nov 20, 25$12.22Nov 24, 25$10.36Nov 26, 25$10.76Dec 1, 25$10.99Dec 3, 25$11.12Dec 5, 25$11.04Dec 9, 25$12.50Dec 11, 25$13.07Dec 15, 25$11.58Dec 17, 25$11.48Dec 19, 25$11.74Dec 23, 25$12.31Dec 26, 25$12.41Dec 31, 25$11.43Jan 5, 26$10.00Jan 7, 26$9.56Jan 9, 26$9.31Jan 13, 26$10.90Jan 15, 26$11.84Jan 20, 26$11.85Jan 22, 26$12.63Jan 26, 26$12.94Jan 28, 26$14.43Jan 30, 26$14.26Feb 3, 26$15.21Feb 5, 26$14.48Feb 9, 26$15.27Feb 11, 26$15.26Feb 17, 26$14.69Feb 19, 26$16.00Feb 23, 26$15.64Feb 25, 26$15.78Feb 27, 26$15.34Mar 3, 26$14.10Mar 5, 26$13.81Mar 9, 26$13.54Mar 11, 26$14.98Mar 13, 26$13.00Mar 17, 26$13.22Mar 19, 26$12.11Mar 23, 26$12.42Mar 25, 26$13.28Mar 27, 26$13.34Apr 1, 26$13.45Apr 6, 26$13.44Apr 8, 26$12.79Apr 10, 26$12.87Apr 14, 26$12.97Apr 16, 26$13.30Apr 20, 26$13.47Apr 22, 26$12.96Apr 24, 26$12.41Apr 28, 26$12.54Apr 30, 26$12.82May 4, 26$14.15May 6, 26$14.94May 8, 26$14.53May 12, 26$13.66May 15, 26$13.72May 19, 26$12.76May 21, 26$14.37May 26, 26$13.70May 28, 26$13.31Jun 1, 26$13.09Jun 3, 26$12.48Jun 5, 26$11.49Jun 9, 26$11.43Jun 11, 26$11.86Jun 15, 26$12.72Jun 17, 26$12.16Jun 22, 26$11.62Jun 24, 26$12.82Jun 30, 26$15.22
$3.7352-week range$16.00
Loading valuation history…

Fundamentals

Key fundamentals

$499.1M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$55.5M

Free cash flow (USD)

-$254.6M

Net debt

Net cash position

7.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2021 → 2025

FY 2021$0.00FY 2022$0.00FY 2023$50.0MFY 2024$0.00FY 2025$0.00
$0$0

Free cash flow by year

2021 → 2025

FY 2021$-26.4MFY 2022$-20.2MFY 2023$18.9MFY 2024$-33.4MFY 2025$-55.5M
-$26.4M-$55.5M

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $595K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $594.6KJul 2, 2026Filing
  • Insider sellInsider Sell $160K · 10b5-1 PlanStengone Carmine N. · Director, CEO and President · $160.1KJul 1, 2026Filing
  • Insider sellInsider Sell $174K · 10b5-1 PlanWatkins Tim · CMO & Head of Development · $173.6KJul 1, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 26, 2026Filing
  • Insider sellInsider Sell $55K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $54.9KJun 1, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventClinical Trial ResultsApr 30, 2026Filing
  • Insider sellInsider Sell $56K · 10b5-1 PlanLorrain Daniel S. · Chief Scientific Officer · $56KApr 6, 2026Filing

Questions

Frequently asked questions

What is Contineum Therapeutics, Inc. Class A Common Stock's market cap?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $499.1M.

What is CTNM's P/E ratio?

A meaningful P/E ratio is not available for CTNM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CTNM's price-to-book (P/B) ratio?

CTNM trades at 1.91 times book value per share.

Are insiders buying CTNM stock?

SEC Form 4 filings show no open-market insider buys at Contineum Therapeutics, Inc. Class A Common Stock in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

AUTL

Autolus Therapeutics plc

$492.4M

FDMT

4D Molecular Therapeutics, Inc.

$506.6M

EBS

Emergent BioSolutions Inc.

$478.8M

XOMA

XOMA Royalty Corp.

$523.3M

ALLO

Allogene Therapeutics, Inc.

$524.6M

OCGN

Ocugen, Inc.

$470M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.